U.S. committee recommends GSK shingles vaccine over Merck rival

The committee responsible for U.S. vaccination schedules has given a preferential recommendation to GlaxoSmithKline's newly approved shingles vaccine Shingrix over Merck & Co's established product Zostavax.The backing from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) follows evidence from clinical trials that Shingrix is significantly more effective than Zostavax, the only currently available shingles prevention vaccine.ACIP members als